» Articles » PMID: 35182208

[Catheter Ablation : Developments and Technique Selection]

Overview
Date 2022 Feb 19
PMID 35182208
Authors
Affiliations
Soon will be listed here.
Abstract

Atrial fibrillation (AF) is the most common arrhythmia and an important risk factor for the occurrence of cardiovascular events. According to current guidelines, rhythm-controlling therapy is recommended only for symptomatic AF. Even in symptomatic AF there is still only a class IIa-recommendation for catheter ablation as initial therapy in paroxysmal AF. Meanwhile, current studies have shown an advantage of the early rhythm control compared to a rate control, as well as a benefit of catheter ablation compared to antiarrhythmic drug (AAD) treatment. The gold standard of catheter ablation for AF therapy is pulmonary vein isolation, which has been mainly radiofrequency-based in the past. However, cryoablation as a first-line therapy of paroxysmal AF is increasingly gaining importance, as the latest studies showed shorter procedure times, lower reintervention rates and improved life quality after cryoablation. Nevertheless, using these standard techniques, the risk of adverse events is still given through collateral damage. The field high-power short duration ablation is currently topic of ongoing AF research, which describes a radiofrequency ablation with higher energy levels, given over shorter duration, with a consecutive lower recurrence rate as well as procedure time. The new ablation techniques also include the pulsed field ablation, which allows ablation through very fast delivery of electrical pulses and causes isolated damage to myocardial cells without collateral damage. This promising technique passed the efficiency and safety testing in preclinical studies. To validate this technique further randomized trials are needed.

Citing Articles

Pulsed Field Ablation to Treat Atrial Fibrillation: A Review of the Literature.

Di Monaco A, Vitulano N, Troisi F, Quadrini F, Romanazzi I, Calvi V J Cardiovasc Dev Dis. 2022; 9(4).

PMID: 35448070 PMC: 9030965. DOI: 10.3390/jcdd9040094.

References
1.
Andrade J, Champagne J, Deyell M, Essebag V, Lauck S, Morillo C . A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale. Am Heart J. 2018; 206:94-104. DOI: 10.1016/j.ahj.2018.05.020. View

2.
Andrade J, Champagne J, Dubuc M, Deyell M, Verma A, Macle L . Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation. 2019; 140(22):1779-1788. DOI: 10.1161/CIRCULATIONAHA.119.042622. View

3.
Barkagan M, Contreras-Valdes F, Leshem E, Buxton A, Nakagawa H, Anter E . High-power and short-duration ablation for pulmonary vein isolation: Safety, efficacy, and long-term durability. J Cardiovasc Electrophysiol. 2018; 29(9):1287-1296. DOI: 10.1111/jce.13651. View

4.
Bourier F, Duchateau J, Vlachos K, Lam A, Martin C, Takigawa M . High-power short-duration versus standard radiofrequency ablation: Insights on lesion metrics. J Cardiovasc Electrophysiol. 2018; 29(11):1570-1575. DOI: 10.1111/jce.13724. View

5.
Bourier F, Takigawa M, Lam A, Vlachos K, Ramirez F, Martin C . Ultralow temperature cryoablation: Safety and efficacy of preclinical atrial and ventricular lesions. J Cardiovasc Electrophysiol. 2021; 32(3):570-577. DOI: 10.1111/jce.14907. View